TY - JOUR
T1 - Weight Loss Strategies for Treatment of Obesity
T2 - Lifestyle Management and Pharmacotherapy
AU - Kushner, Robert F.
N1 - Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2018/7/1
Y1 - 2018/7/1
N2 - Obesity is one of the most serious and prevalent non-communicable diseases of the twenty-first century. It is also a patient-centered condition in which affected individuals seek treatment through a variety of commercial, medical and surgical approaches. Considering obesity as a chronic medical disease state helps to frame the concept of using a three-stepped intensification of care approach to weight management. As a foundation, all patients should be counseled on evidence-based lifestyle approaches that include diet, physical activity and behavior change therapies. At the second tier, four new pharmacological agents, lorcaserin, phentermine/topiramate, naltrexone/bupropion and liraglutide have been approved since 2012 as adjuncts to lifestyle modification. The third step, bariatric surgery, has been demonstrated to be the most effective and long-term treatment for individuals with severe obesity or moderate obesity complicated by co-morbid conditions that is not responsive to non-surgical approaches. By using a medical model, clinicians can provide more proactive and effective treatments in assisting their patients with weight loss.
AB - Obesity is one of the most serious and prevalent non-communicable diseases of the twenty-first century. It is also a patient-centered condition in which affected individuals seek treatment through a variety of commercial, medical and surgical approaches. Considering obesity as a chronic medical disease state helps to frame the concept of using a three-stepped intensification of care approach to weight management. As a foundation, all patients should be counseled on evidence-based lifestyle approaches that include diet, physical activity and behavior change therapies. At the second tier, four new pharmacological agents, lorcaserin, phentermine/topiramate, naltrexone/bupropion and liraglutide have been approved since 2012 as adjuncts to lifestyle modification. The third step, bariatric surgery, has been demonstrated to be the most effective and long-term treatment for individuals with severe obesity or moderate obesity complicated by co-morbid conditions that is not responsive to non-surgical approaches. By using a medical model, clinicians can provide more proactive and effective treatments in assisting their patients with weight loss.
KW - Diet
KW - Lifestyle
KW - Obesity
KW - Pharmacology
UR - http://www.scopus.com/inward/record.url?scp=85049451440&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049451440&partnerID=8YFLogxK
U2 - 10.1016/j.pcad.2018.06.001
DO - 10.1016/j.pcad.2018.06.001
M3 - Review article
C2 - 29890171
AN - SCOPUS:85049451440
SN - 0033-0620
VL - 61
SP - 246
EP - 252
JO - Progress in Cardiovascular Diseases
JF - Progress in Cardiovascular Diseases
IS - 2
ER -